合作
Taysha Gene Therapies and Catalent Expand Strategic Partnership for Commercial Manufacturing of TSHA-102
Catalent will serve as Taysha's primary commercial manufacturer following potential U.S. FDA approval of TSHA-102, providing GMP manufacturing and commercial supply at its FDA-licensed commercial gene therapy facility in Harmans, Maryland.
大盤 開啟原文 ↗